>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

2.21 -0.01 (-0.45%) 09/04/2026
Equillium, Inc. (EQ)
Performance
Historical returns
1D
-0.45%
1W
-2.64%
1M
-2.21%
3M
-30.28%
6M
26.29%
1Y
26.29%
5Y
-60.88%
Snapshot
Key statistics
Close
2.21
Change
-0.01
Change %
-0.45%
Open
2.22
Day Range
2.20 – 2.25
Volume
225,910
Avg Vol (20d)
429,286
Rel Vol
0.53x
52W Range
0.76 - 3.54
vs 52W High
-37.57%
vs 52W Low
192.25%
Gap
-0.09
Market Cap
USD 139.73M
Beta
1.88
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
5 bullish · 3 bearish points
Bullish view
  • Holds 11.2% above its 200-day average.
  • Has recovered 163.1% off the 52-week low of $0.84.
  • FY2025 earnings rose 177.6% to -$22.40M.
  • Sits 182.8% below the average analyst target of $6.25 across 4 firms.
  • The Q2 '26 quarter beat on EPS by $0.01 (25.9% above consensus).
Bearish view
  • Still 30.9% below its 52-week high of $3.20.
  • Lagged the S&P 500 by 29.5% over the last quarter (-24.8% against +4.7%).
  • Full-year revenue declined 100.0% in FY2025 to $0.00.
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Sep 4
2026
$2.21 0.45%Latest
Equillium fell 0.45% to $2.21, though on light volume (0.5× the 20-day average). Shares closed near the session low (20% of the day's range). The move left the stock 30.9% below its 52-week high.
Aug 26
2026
$2.36 8.26%
Equillium rose 8.26% to $2.36, a 1.6σ move against its 60-day volatility, on 1.4× average volume. This was largely stock-specific: the S&P 500 gained 0.02% while Healthcare peers (XLV) fell 1.00% that session, leaving about 8.2 points of the move unexplained by the market after adjusting for a 1.88 beta. Shares reclaimed their 20-day moving average.
Aug 24
2026
$2.20 4.76%
Equillium fell 4.76% to $2.20, though on light volume (0.6× the 20-day average). This was largely stock-specific: the S&P 500 fell 0.29% while Healthcare peers (XLV) rose 0.05% that session, leaving about 4.2 points of the move unexplained by the market after adjusting for a 1.88 beta. Shares opened with a 0.87% gap down, closed near the session low (19% of the day's range) and lost their 20-day moving average.
Aug 17
2026
$2.48 5.08%Earnings
Equillium rose 5.08% to $2.48, though on light volume (0.5× the 20-day average). This was largely stock-specific: the S&P 500 fell 0.47% while Healthcare peers (XLV) fell 0.19% that session, leaving about 5.3 points of the move unexplained by its sector. Shares opened with a 1.91% gap down and reversed through the session and closed near the session high (95% of the day's range). It came 2 sessions after the Q2 2026 print.
Aug 14
2026
$2.36 17.41%Earnings
Equillium rose 17.41% to $2.36, its biggest one-day gain in 5 months and a 3.2σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.20% while Healthcare peers (XLV) fell 0.60% that session, leaving about 17.8 points of the move unexplained by the market after adjusting for a 1.88 beta. Shares opened with a 1.00% gap up, closed near the session high (99% of the day's range) and reclaimed their 20-day moving average. This was the first session after Q2 2026 results: EPS of $-0.04 vs $-0.05 expected (a beat). Historically, after 2.5σ-or-larger up days, Equillium returned -0.21% on average over the following 5 sessions (42% positive, n=19).
Aug 13
2026
$2.01 7.80%Pre-Earnings
Equillium fell 7.80% to $2.01, its biggest one-day drop in 2 months. This was largely stock-specific: the S&P 500 gained 0.70% while Healthcare peers (XLV) fell 0.04% that session, leaving about 7.8 points of the move unexplained by its sector. Shares closed near the session low (12% of the day's range). The session traded into Q2 2026 results, released after the close that evening.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month1.98 +11.62%
on 08/13/26
Open 2.12
2.55 -13.33%
on 08/18/26
+0.09 (+4.25%)
since 08/06/26
3-Month1.98 +11.62%
on 08/13/26
Open 2.94
3.54 -37.57%
on 06/30/26
-0.73 (-24.83%)
since 06/05/26
6-Month1.60 +38.13%
on 03/30/26
Open 1.77
3.54 -37.57%
on 06/30/26
+0.44 (+24.86%)
since 03/06/26
YTD1.05 +110.48%
on 01/15/26
Open 1.53
3.54 -37.57%
on 06/30/26
+0.68 (+44.44%)
since 01/02/26
52-Week0.76 +192.25%
on 11/14/25
Open 1.75
3.54 -37.57%
on 06/30/26
+0.46 (+26.29%)
since 09/04/25
5-Year0.27 +718.52%
on 06/24/25
Open 6.24
7.12 -68.96%
on 10/06/21
-4.03 (-64.58%)
since 08/27/21
New Highs
Historical highs
5-Day
0×
-2.64% from peak
1-Month
4×
-10.89% from peak
3-Month
5×
-30.94% from peak
6-Month
10×
-30.94% from peak
YTD
17×
-30.94% from peak
52-Week
12×
-30.94% from peak
2-Year
22×
-30.94% from peak
3-Year
16×
-30.94% from peak
5-Year
7×
-68.38% from peak
10-Year
n/a
not enough history
Financial SnapshotFY 2025
Full financials
Revenue
n/a
-100.0% YoY
Net Income
-USD 22.40M
+177.6% YoY
EPS
-0.39
+69.6% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 22.28M
Free Cash Flow
-USD 22.79M
ROE
-78.3%
ROA
-70.2%
Debt / Equity
0.03x
net debt -USD 29.56M
Cash & Equiv.
USD 30.28M
News
All news
09/02 08:30 ET · globenewswire.com
Equillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor...
08/13 16:05 ET · globenewswire.com
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a...
08/10 04:15 ET · defenseworld.net
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Equillium, Inc. (NASDAQ: EQ - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, seven have assigned a buy recommendation...
06/18 08:00 ET · accessnewswire.com
EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake
Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June 18, 2026 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data-driven...
06/02 16:05 ET · globenewswire.com
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an...
06/01 22:14 ET · seekingalpha.com
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
05/29 11:05 ET · marketbeat.com
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflammatory disease biology.
05/28 16:05 ET · globenewswire.com
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare...

Market News ×
Loading news…